- Home
- ABEO vs ARQQ Comparison
ABEO vs ARQQ Comparison
Compare ABEO & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | ARQQ |
|---|---|---|
| Founded | 1974 | 2017 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 348.7M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABEO | ARQQ |
|---|---|---|
| Price | $5.97 | $21.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $20.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 1.5M | 230.0K |
| Earning Date | 05-13-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | $381.13 |
| Revenue Next Year | $145.42 | $212.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $11.52 |
| 52 Week High | $7.65 | $62.00 |
Technical Indicators
Market Signals| Indicator | ABEO | ARQQ |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 48.05 |
| Support Level | $5.83 | $15.50 |
| Resistance Level | $5.97 | $24.90 |
| Average True Range (ATR) | 0.21 | 1.49 |
| MACD | -0.04 | -0.29 |
| Stochastic Oscillator | 34.68 | 26.53 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.